腹腔穿刺用于血红蛋白病的早期产前诊断
本研究前瞻性纳入402例单胎妊娠,父母双方均为β地中海贫血或镰状细胞病特质携带者,在孕6.9-9.9周行腹腔穿刺产前诊断。结果显示取样成功率达99.8%,93.8%病例获得诊断结果,持续妊娠活产率97.1%,操作相关妊娠并发症风险较低。
要点
- 腹腔穿刺可在孕7周起用于单基因病的早期产前诊断。
- 取样成功率99.8%,诊断成功率93.8%,近121例均成功。
- 持续妊娠活产率97.1%,流产率2.3%,操作相关风险较低。
核心结论
- 腹腔穿刺可用于遗传异常的早期产前诊断,操作相关妊娠并发症风险似乎较低。
研究设计与样本
- 前瞻性研究,纳入402例单胎妊娠,父母双方均为β地中海贫血或镰状细胞病特质携带者。
- 腹腔穿刺中位孕周8.6周(范围6.9-9.9周)。
主要发现
- 腹腔液取样成功率为99.8%。
- 67%孕妇无不适或仅轻度不适,18%中度不适,12%轻至中度疼痛,3%重度疼痛。
- 腹腔液分析产前诊断成功率为93.8%,最后121例均成功。
- 所有取样和分析成功病例的诊断与额外产前或产后检测结果一致。
- 持续妊娠中活产298/307(97.1%),流产7例(2.3%),失访2例(0.7%)。
关键数值与推荐
- 定量荧光聚合酶链反应分析使用X、Y、21、18和13号染色体多个标记评估母体污染,并准确诊断染色体非整倍体。
- 因腹腔穿刺诊断受累胎儿而选择终止妊娠的病例均在孕10周前完成。
临床怎么用
- 对于父母双方均为β地中海贫血或镰状细胞病特质携带者的单胎妊娠,可考虑在孕7周后行腹腔穿刺进行早期产前诊断。
- 腹腔穿刺操作相关疼痛多为无或轻度,严重疼痛少见。
- 腹腔液分析可同时评估血红蛋白病和染色体非整倍体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Celocentesis is an invasive technique that can provide prenatal diagnosis of single-gene disorders, from as early as 7 weeks' gestation. The objective of this study was to examine the safety of celocentesis. METHODS: In this prospective study, celocentesis was performed for prenatal diagnosis of hemoglobinopathy in 402 singleton pregnancies in which both parents were carriers of β-thalassemia or sickle cell disease trait. We assessed procedure-related maternal discomfort or pain, success of sampling and obtaining results, pregnancy outcome and postnatal follow-up. RESULTS: First, celocentesis was carried out at a median gestational age of 8.6 (range, 6.9-9.9) weeks and celomic fluid was successfully aspirated in 99.8% of cases. Second, 67% of women had no or only mild discomfort, 18% had moderate discomfort, 12% had mild-to-moderate pain and 3% had severe pain. Third, prenatal diagnosis from analysis of the celomic fluid was successful in 93.8% cases, and in the last 121 cases, it was always successful. Fourth, in all cases of successful sampling and analysis of celomic fluid, the diagnosis was concordant with results obtained from additional prenatal or postnatal testing. Fifth, in addition to diagnosis of hemoglobinopathy, quantitative fluorescence polymerase chain reaction analysis, which was performed to evaluate maternal contamination using several markers for chromosomes X, Y, 21, 18 and 13, led to the accurate diagnosis of chromosomal aneuploidy. Sixth, in all cases of an affected fetus diagnosed by celocentesis in which the parents chose termination of pregnancy, this was carried out < 10 weeks' gestation. Seventh, in 97.1% (298/307) of the continuing pregnancies there was live birth, in seven (2.3%) there was miscarriage and in two (0.7%) there was loss to follow-up. Eighth, fetal abnormalities were diagnosed in three (1%) cases, including unilateral transverse amputation of the forearm, unilateral moderate hydronephrosis and small-bowel duplication. All neonates were examined by a pediatrician and were found to be phenotypically normal, except for the three cases with a prenatally diagnosed defect. CONCLUSIONS: Celocentesis can be used for early prenatal diagnosis of genetic abnormalities, and the procedure-related risk of pregnancy complications appears to be low. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Makrydimas G, Damiani G, Jakil C, et al. Celocentesis for early prenatal diagnosis of hemoglobinopathy. Ultrasound Obstet Gynecol. 2020. PMID: 32339311. doi:10.1002/uog.22059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。